A major fiasco made 2016 a tough year to be a Juno Therapeutics (NASDAQ: JUNO) shareholder. Shares of the clinical-stage biotech have fallen about 32% over the past 12 months. In contrast, its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results